Access to Affordable Medicines and Diagnostic Tests for Asthma and COPD in Sub Saharan Africa

dc.contributor.authorKibirige, Davis
dc.contributor.authorKampiire, Leaticia
dc.contributor.authorAtuhe, David
dc.contributor.authorMwebaze, Raymond
dc.contributor.authorKatagira, Winceslaus
dc.contributor.authorMuttamba, Winters
dc.contributor.authorNantanda, Rebecca
dc.contributor.authorWorodria, William
dc.contributor.authorKirenga, Bruce
dc.date.accessioned2021-04-22T08:03:30Z
dc.date.available2021-04-22T08:03:30Z
dc.date.issued2017-12-08
dc.description.abstractBackground: Equitable access to affordable medicines and diagnostic tests is an integral component of optimal clinical care of patients with asthma and chronic obstructive pulmonary disease (COPD). In Uganda, we lack contemporary data about the availability, cost and affordability of medicines and diagnostic tests essential in asthma and COPD management. Methods: Data on the availability, cost and affordability of 17 medicines and 2 diagnostic tests essential in asthma and COPD management were collected from 22 public hospitals, 23 private and 85 private pharmacies. The percentage of the available medicines and diagnostic tests, the median retail price of the lowest priced generic brand and affordability in terms of the number of days’ wages it would cost the least paid public servant were analysed. Results: The availability of inhaled short acting beta agonists (SABA), oral leukotriene receptor antagonists (LTRA), inhaled LABA-ICS combinations and inhaled corticosteroids (ICS) in all the study sites was 75%, 60.8%, 46.9% and 45.4% respectively. None of the study sites had inhaled long acting anti muscarinic agents (LAMA) and inhaled long acting beta agonist (LABA)-LAMA combinations. Spirometry and peak flow-metry as diagnostic tests were available in 24.4% and 6.7% of the study sites respectively. Affordability ranged from 2.2 days’ wages for inhaled salbutamol to 17.1 days’ wages for formoterol/budesonide inhalers and 27.8 days’ wages for spirometry. Conclusion: Medicines and diagnostic tests essential in asthma and COPD care are not widely available in Uganda and remain largely unaffordable. Strategies to improve access to affordable asthma and COPD medicines and diagnostic tests should be implemented in Uganda.en_US
dc.identifier.citationKibirige, D., Kampiire, L., Atuhe, D., Mwebaze, R., Katagira, W., Muttamba, W., Nantanda, R., Worodria, W. and Kirenga, B., 2017. Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective. BMC pulmonary medicine, 17(1), pp.1-10.en_US
dc.identifier.issn1471-2466
dc.identifier.urihttp://hdl.handle.net/20.500.12280/2688
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofseriesBMC pulmonary medicine;17(1)
dc.subjectAccessen_US
dc.subjectMedicinesen_US
dc.subjectDiagnostic testsen_US
dc.subjectAsthmaen_US
dc.subjectCOPDen_US
dc.subjectSub Saharan Africaen_US
dc.subjectUgandaen_US
dc.titleAccess to Affordable Medicines and Diagnostic Tests for Asthma and COPD in Sub Saharan Africaen_US
dc.title.alternativeThe Ugandan Perspectiveen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mwebaze_ARTICLE_MKPGS_2017_Access to.pdf
Size:
591.2 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: